UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 傍神経節腫および褐色細胞腫：悪性疾患のマネージメント paraganglioma and pheochromocytoma management of malignant disease
- 2. 分化型甲状腺癌：放射性ヨード治療 differentiated thyroid cancer radioiodine treatment
- 3. バセドウ病（グレーブス甲状腺機能亢進症）の治療 treatment of graves hyperthyroidism
- 4. 切除可能な肝細胞癌のマネージメント：予後、術前補助化学療法と補助化学療法の役割、
および治療後サーベイランス management of potentially resectable hepatocellular carcinoma prognosis role of neoadjuvant and adjuvant therapy and posttreatment surveillance - 5. 傍神経節腫：疫学、臨床症状、診断、および組織学的検査 paragangliomas epidemiology clinical presentation diagnosis and histology
English Journal
- Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).
- Trieu M1, DuBois SG1, Pon E1, Nardo L2, Hawkins RA2, Marachelian A3, Twist CJ4, Park JR5, Matthay KK1.
- Pediatric blood & cancer.Pediatr Blood Cancer.2016 Mar;63(3):436-42. doi: 10.1002/pbc.25816. Epub 2015 Oct 27.
- BACKGROUND: (131) I-metaiodobenzylguanidine ((131) I-MIBG) is a targeted radiopharmaceutical for patients with neuroblastoma. Despite its tumor-specific uptake, the treatment with (131) I-MIBG results in whole-body radiation exposure. Our aim was to correlate whole-body radiation dose (WBD) from (13
- PMID 26506090
- Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
- Modak S1, Zanzonico P2, Carrasquillo JA3, Kushner BH4, Kramer K4, Cheung NK4, Larson SM3, Pandit-Taskar N3.
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine.J Nucl Med.2016 Feb;57(2):231-7. doi: 10.2967/jnumed.115.161752. Epub 2016 Jan 7.
- Arsenic trioxide has in vitro and in vivo radiosensitizing properties. We hypothesized that arsenic trioxide would enhance the efficacy of the targeted radiotherapeutic agent (131)I-metaiodobenzylguanidine ((131)I-MIBG) and tested the combination in a phase II clinical trial.METHODS: Patients with r
- PMID 26742708
- Adrenal Molecular Imaging.
- Sundin A1.
- Frontiers of hormone research.Front Horm Res.2016;45:70-9. doi: 10.1159/000442317. Epub 2016 Mar 15.
- The major workload in the field of adrenal imaging comprises patients with adrenal tumors incidentally depicted by imaging performed for other reasons than adrenal disease. These so-called 'incidentalomas' are generally managed by CT and MRI, and molecular imaging techniques are required only for a
- PMID 27003680
Japanese Journal
- Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry
- Yoshinaga Keiichiro,Oriuchi Noboru,Wakabayashi Hiroshi,Tomiyama Yuuki,Jinguji Megumi,Higuchi Tetsuya,Kayano Daiki,Fukuoka Makoto,Inaki Anri,Toratani Ayane,Okamoto Shozo,Shiga Tohru,Ito Yoichi M.,Nakajo Masatoyo,Nakajo Masayuki,Kinuya Seigo
- Endocrine Journal 61(12), 1171-1180, 2014
- … While iodine-131 metaiodobenzylguanidine (131I-MIBG) radiotherapy has been used in the treatment of malignant neuroendocrine tumors, there are few studies evaluating its therapeutic effects and safety in a multicenter cohort. … In the current study, we sought to evaluate the effects and safety of 131I-MIBG therapy for conditions including malignant pheochromocytoma and paraganglioma within a multicenter cohort. …
- NAID 130004770440
- Effects and safety of 131I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: Results from a multicenter observational registry
- Yoshinaga Keiichiro,Oriuchi Noboru,Wakabayashi Hiroshi,Tomiyama Yuuki,Jinguji Megumi,Higuchi Tetsuya,Kayano Daiki,Fukuoka Makoto,Inaki Anri,Toratani Ayane,Okamoto Shozo,Shiga Tohru,Ito Yoichi M.,Nakajo Masatoyo,Nakajo Masayuki,Kinuya Seigo
- Endocrine Journal, 2014
- … While iodine-131 metaiodobenzylguanidine (131I-MIBG) radiotherapy has been used in the treatment of malignant neuroendocrine tumors, there are few studies evaluating its therapeutic effects and safety in a multicenter cohort. … In the current study, we sought to evaluate the effects and safety of 131I-MIBG therapy for conditions including malignant pheochromocytoma and paraganglioma within a multicenter cohort. …
- NAID 130004687425
- Low-dose 123I-metaiodobenzylguanidine diagnostic scan is inferior to 131I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma
- Kayano Daiki,Taki Junichi,Fukuoka Makoto,Wakabayashi Hiroshi,Inaki Anri,Nakamura Ayane,Kinuya Seigo
- Nuclear Medicine Communications 32(10), 941-946, 2011-10
- … OBJECTIVE: We assessed the lesion detectability of low-dose diagnostic 123I-metaiodobenzylguanidine (MIBG) whole-body scans obtained at 6 and 24 h compared with posttreatment 131I-MIBG whole-body scans in malignant pheochromocytoma and paraganglioma. … Therapeutic doses of 131I-MIBG (5.55-7.40 GBq) were administrated and whole-body scans were obtained at 2-5 days after 123I-MIBG administrations. …
- NAID 120003386976
Related Links
- A Garaventa,1 O Bellagamba,1 M S Lo Piccolo,1 C Milanaccio,1 E Lanino,1 L Bertolazzi,2 G P Villavecchia,2 M Cabria,2 G Scopinaro,2 F Claudiani,2 and B De Bernardi1. 1Department of Haematology–Oncology, Giannina Gaslini Children's ...
- PURPOSE: The analogue 131I-metaiodobenzylguanidine (MIBG), which is specifically targeted to neuroblastoma cells, may provide more effective and less toxic treatment for neuroblastoma than conventional external-beam radiotherapy.
Related Pictures
★リンクテーブル★
| リンク元 | 「131I-メタヨードベンジルグアニジン」 |
| 関連記事 | 「131I」「metaiodobenzylguanidine」 |
「131I-メタヨードベンジルグアニジン」
「131I」
- 英
- iodine-131
- 同
- radioiodine-131、ヨウ素-131、ヨウ素131
- 関
- 放射性核種、ヨウ素
- 治療を目的として用いられる(放射線ヨード療法)：バセドウ病、甲状腺癌 → 被曝が大きいので
- 半減期：8 d
- 壊変様式：β- β崩壊
- 13153I → + e- + νe
- 中性子が陽子、β線(電子)、反電子ニュートリノに変換。